Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELEASE Norway aspirin continuation versus discontinuation trial in elderly secondary coronary artery disease prevention
2026-526941-91-00Phase 4Authorised
- Sponsor
- Vestre Viken Hospital Trust
- Start
- Sep 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aspirin in Chronic Coronary Syndrome (CCS) and coronary arteriosclerosis (2 arms), sponsored by Vestre Viken Hospital Trust. Primary endpoint: Hierarchical composite clinical outcome. Planned start Sep 2026; status: authorised.
02
Drugs
aspirin
03
Conditions
Chronic Coronary Syndrome (CCS)coronary arteriosclerosis
Beyond the preview
Go deeper on 2026-526941-91-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526941-91-00.